Weight Loss
Weight Loss Research Peptides
Research peptides for weight management and metabolic health.
About Weight Loss Peptides
Explore our selection of weight loss research peptides from Phiogen. All products are for research use only.
Research Applications
These peptides have been studied in various research contexts related to weight loss.
The Receptor Agonist Progression
GLP-1 → Dual → Triple Agonism
Each additional receptor target adds a complementary mechanism, producing progressively greater fat loss in clinical research.
~15%
avg body wt loss
GLP-1 Agonist
Semaglutide (reference)Reduces appetite, slows gastric emptying, stimulates insulin
~20–22%
avg body wt loss
Dual Agonist
Tirzepatide (GLP-1 + GIP)Adds GIP receptor — enhances insulin sensitivity + energy expenditure
~24%
avg body wt loss
Triple Agonist
Retatrutide (GLP-1 + GIP + GCG)Adds glucagon — increases energy expenditure + hepatic fat breakdown
Distinct Pathways
Four Independent Fat-Loss Mechanisms
GLP-1 / GIP / Glucagon Agonism
Reduce caloric intake through satiety signaling, slow stomach emptying, and improve insulin sensitivity.
GH Fragment Lipolysis
Activates beta-3 adrenergic receptors in adipose tissue, triggering fat breakdown without GH's anabolic effects.
NNMT Inhibition
Raises intracellular NAD+ and activates SIRT1/AMPK. Shifts fat cells from energy storage to energy expenditure.
AMPK Activation
Mimics the cellular effects of exercise at the enzyme level — increases fatty acid oxidation and mitochondrial biogenesis.
Research Data
Clinical & Preclinical Highlights
Shop Weight Loss Peptides
Research-grade quality — COA verified. For research use only.
Shop Research PeptidesWeight Loss Peptides (50)
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes sustained weight loss.
Dual GIP/GLP-1 receptor agonist delivering superior weight loss compared to single-agonist approaches.
Oral capsule form of 5-Amino-1MQ for convenient metabolic research.
Promotes fat loss by blocking NNMT enzyme to accelerate fat breakdown.
AMPK activator that mimics the metabolic effects of exercise.
Modified fragment of human growth hormone that targets abdominal fat reduction without IGF-1-related side effects.
High-dose Adipotide (FTPP) for advanced fat loss research.
Pro-apoptotic peptide that selectively targets blood vessels feeding white adipose tissue.
Mitochondrial uncoupler that dissipates the proton gradient as heat to increase metabolic rate and fat oxidation.
High-dose Cagrilintide + Retatrutide blend for extended metabolic obesity research.
Cagrilintide + Retatrutide synergy blend for powerful weight loss research.
Cagrilintide 5mg + Semaglutide blend combining amylin and GLP-1 receptor agonism.
High-dose Cagrilintide amylin analogue for extended appetite and weight research.
Long-acting amylin analogue that reduces appetite, slows gastric emptying, and complements GLP-1-based weight loss protocols.
Ipamorelin 5mg + Tesamorelin 10mg body composition stack.
Ipamorelin 3mg + Tesamorelin 10mg blend targeting visceral fat reduction and lean mass.
Higher-dose Ipamorelin 5mg + Tesamorelin 10mg blend for comprehensive GH and visceral fat research.
Injectable L-Carnitine at 400mg/mL concentration.
Five-vial pack of L-Carnitine 600mg/mL for extended research.
High-concentration injectable L-Carnitine at 600mg/mL.
Mitochondria-derived peptide that activates AMPK and restores metabolic homeostasis.
High-dose MOTS-c for extended mitochondrial and metabolic research.
Bulk MOTS-c for longitudinal mitochondrial signaling and longevity studies.
Dual GLP-1/glucagon receptor agonist promoting sustainable weight reduction through appetite suppression and enhanced energy expenditure.
Pan-AMPK activator that mimics exercise-induced metabolic benefits.
Retatrutide 5mg + Cagrilintide 5mg balanced dual-compound stack.
Triple GLP-1/GIP/glucagon receptor agonist for powerful metabolic research.
Extended-supply SLU-PP-332 capsules (100mg x120).
ERR-alpha/gamma agonist that mimics the metabolic effects of endurance exercise.
High-concentration injectable SLU-PP-332 for advanced exercise-mimetic research.
High-dose Semaglutide for extended GLP-1 receptor agonist research.
Large-format Semaglutide vial for prolonged obesity and metabolic research.
GLP-1/glucagon dual receptor agonist with potent metabolic effects.
GHRH analogue clinically proven to reduce visceral/abdominal fat.
High-dose Tesamorelin for extended visceral fat and GH axis research.
Triple monoamine reuptake inhibitor (serotonin, dopamine, noradrenaline) that reduces appetite through central nervous system mechanisms.
Tablet form Tesofensine for CNS-mediated appetite suppression research.
Mid-range Tirzepatide supply for extended dual incretin research.
Bulk Tirzepatide for comprehensive longitudinal metabolic studies.
Peptide Cycles
Try a Pre-Built Research Cycle
Synergistic combinations of weight loss peptides.
Frequently Asked Questions
What are Weight Loss peptides?
Are these peptides safe?
Start Your Weight Loss Research
50 research peptides available — COA verified, research grade.
For research use only. Not for human consumption. Consult a physician.